Errata (DOI:10.1016/S1470-2045(06)70725-2);Where next for gefitinib in patients with lung cancer?

Lancet Oncology

Volumn 7, Issue 6, 2006, Pages 499-507

  Blackhall, Fiona ^a   Ranson, Malcolm ^a   Thatcher, Nick ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; PLACEBO; PLATINUM DERIVATIVE; TEMOZOLOMIDE; VANDETANIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ASIAN; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; DIARRHEA; DRUG APPROVAL; DRUG ERUPTION; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TOXICITY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MONOTHERAPY; OVERALL SURVIVAL; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; SMOKING;

EID: 33646888233     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(07)70218-8     Document Type: Erratum

References (57)

1. Schottenfeld D. Lung cancer: principles and practice. In: HI Pass J., Johnson D., Turrisi A., and Minna J. (Eds). Etiology and epidemiology of lung cancer. 2nd edn. (2000), Lippincott Williams and Wilkins, Philadelphia 367-397
2. Blackhall F., Shepherd F., and Albain K. Improving survival and reducing toxicity with chemotherapy in advanced non-small-cell lung cancer: a realistic goal?. Treat Respir Med 4 (2005) 71-84
3. Hanna N., Shepherd F., Fossella F., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
4. Massarelli E., Andre F., Liu D., et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39 (2003) 55-61
5. Mendelsohn J., and Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (2000) 6550-6565
6. Cappuzzo F., Hirsch F., Rossi E., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
7. Shigematsu H., and Gazdar A. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 118 (2006) 257-262
8. Sridhar S., Seymour L., and Shepherd F. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4 (2003) 397-406
9. Ranson M. Epidermal growth factor receptor tyrosine kinase inhibitors. Br J Cancer 90 (2004) 2250-2255
10. Fukuoka M., Yano S., Giaccone G., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 trial) [corrected]. J Clin Oncol 21 (2003) 2237-2246
11. Kris M., Natale R., Herbst R., et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290 (2003) 2149-2158
12. Shepherd F., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 123-132
13. Perez-Soler R., Chachoua A., Hammond L., et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22 (2004) 3238-3247
14. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537
15. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20 (2002) 4292-4302
16. Goss G., Hirte H., Miller Jr. W., et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the investigational new drug program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 23 (2005) 147-155
17. Herbst R., Maddox A., Rothenberg M., et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 20 (2002) 3815-3825
18. Nakagawa K., Tamura T., Negoro S., et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 14 (2003) 922-930
19. Ranson M., Hammond L., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
20. Albanell J., Rojo F., Averbuch S., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20 (2002) 110-124
21. Wolf M., Swaisland H., and Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 10 (2004) 4607-4613
22. Cella D., Herbst R., Lynch T., et al. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol 23 (2005) 2946-2954
23. Shepherd F., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
24. Giaccone G., Herbst R., Manegold C., et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 22 (2004) 777-784
25. Herbst R., Giaccone G., Schiller J., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 22 (2004) 785-794
26. Herbst R., Prager D., Hermann R., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23 (2005) 5892-5899
27. Gatzemeier U., Pluzanska A., Szczesna A., et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 23 (2004) abstr 617
28. Kelly K., Gaspar L., Chansky K., et al. Low incidence of pneumonitis on SWOG 0023: a preliminary analysis of an ongoing phase III trial of concurrent chemoradiotherapy followed by consolidation docetaxel and Iressa/placebo maintenance in patients with inoperable stage III non-small cell lung cancer. Proc Am Soc Clin Oncol 23 (2005) abstr 7058
29. NCIC-Clinical Trials Group. Phase III Randomized Study of Adjuvant Gefitinib in Patients With Completely Resected Primary Stage IB, II, or IIIA Non-Small Cell Lung Cancer. http://www.cancer.gov/clinicaltrials/CAN-NCIC-BR19 (accessed May 15, 2006)
30. Lynch T., Bell D., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
31. Paez J., Janne P., Lee J., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
32. Pao W., Miller V., Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101 (2004) 13306-13311
33. Tsao M., Sakurada A., Cutz J., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
34. Hirsch F, Varella-Garcia M, Bunn P, et al. Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small cell lung cancer treated with gefitinib or placebo (ISEL trial). AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, 2005; Philadelphia, PA, USA: abstr A268.
35. Holloway B, Thatcher N, Chang A, et al. Epidermal growth factor (EGFR), Kras and Braf mutation status and clinical outcome to gefitinib (Iressa) in a phase III placebo-controlled study (ISEL) in advanced non-small cell lung cancer (aNSCLC). Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics, 2005; Philadelphia, PA, USA: abstr A269.
36. Janne P., Engelman J., and Johnson B. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23 (2005) 3227-3234
37. Siegel-Lakhai W., Beijnen J., and Schellens J. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist 10 (2005) 579-589
38. University Health Network, Toronto. Phase 2 study of neoadjuvant Iressa treatment in stage 1 NSCLC. http://www.clinicaltrials.gov/ct/show/NCT00188617 (accessed May 15, 2006)
39. National Cancer Institute. Gefitinib and radiation therapy in treating patients with inoperable stage I or stage II non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00268255 (accessed May 15, 2006)
40. AstraZeneca. Iressa vs placebo as maintenance therapy in locally advanced NSCLC. http://www.clinicaltrials.gov/ct/show/NCT00234468 (accessed May 15, 2006)
41. National Cancer Institute. Gefitinib as first-line therapy followed by gemcitabine and cisplatin in treating patients with stage III or stage IV non-small cell lung cancer. http://www.clinicaltrials.gov/ct/gui/show/NCT00217698 (accessed May 15, 2006)
42. National Cancer Institute. Gefitinib after chemotherapy in treating patients with stage IIIB or stage IV non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00091156 (accessed May 15, 2006)
43. National Taiwan University Hospital. Iressa as a first-line treatment in chemonaive patients with inoperable non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00173875 (accessed May 15, 2006)
44. National Cancer Institute. Gefitinib with or without carboplatin and paclitaxel in treating older patients with unresectable or metastatic non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00062062 (accessed May 15, 2006)
45. H Lee Moffitt Cancer Center and Research Institute. Phase II study of docetaxel + ZD1839 in elderly patients with non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00231465?order=6 (accessed May 15, 2006)
46. AstraZeneca. Phase II Iressa versus vinorelbine (INVITE). http://www.clinicaltrials.gov/ct/show/NCT00256711?order=1 (accessed May 15, 2006)
47. AstraZeneca. Phase II Iressa and carbo/gem in NSCLC. http://www.clinicaltrials.gov/ct/show/NCT00264498?order=9 (accessed May 15, 2006)
48. AstraZeneca. Iressa vs BSC (best supportive care) in first line NSCLC. http://www.clinicaltrials.gov/ct/show/NCT00259064?order=89 (accessed May 15, 2006)
49. AstraZeneca. A phase I study of ZD1839 and palliative thoracic radiotherapy in patients with non-small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00255489 (accessed May 15, 2006)
50. Cappuzzo F., Calandri C., Bartolini S., and Crino L. ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases. Br J Cancer 89 (2003) 246-247
51. National Cancer Institute. Radiation therapy combined with either gefitinib or temozolomide in treating patients with non-small cell lung cancer and brain metastases. http://www.clinicaltrials.gov/ct/show/NCT00238251 (accessed May 15, 2006)
52. AstraZeneca. Iressa in the treatment of brain metastases from non small cell lung cancer. http://www.clinicaltrials.gov/ct/show/NCT00234442 (accessed May 15, 2006)
53. Cufer T., Vrdoljak E., Gaafar R., et al. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stage IIIB or IV) non-small-cell lung cancer. Anticancer Drugs 17 (2006) 401-409
54. AstraZeneca. Iressa versus docetaxel (Taxotere). http://www.clinicaltrials.gov/ct/show/NCT00076388 (accessed May 15, 2006)
55. AstraZeneca. Iressa 2nd line phase III study in Japan. http://www.clinicaltrials.gov/ct/show/NCT00252707 (accessed May 15, 2006)
56. Sandler A., Gray R., Brahmer J., et al. Randomised phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-E4599. Proc Am Soc Clin Oncol 23 (2005) abstr 4
57. Natale R., Bodkin D., Govindan R., et al. A comparison of the antitumour efficacy of ZD6474 and gefitinib (Iressa) in patients with NSCLC: Results of a double-blind phase II study. Lung Cancer 49 suppl 2 (2005) S37